DRUG RECALLS: DECEMBER 2010
DECEMBER 2010: REESE PHARMACEUTICAL COMPANY OTC PRODUCTS RECALLED DUE TO MISLABELED GUAIFENESIN TABLETS. HERE ARE THE PRODUCTS THAT WERE RECALLED AS FOLLOWING:
- Refenesen Expectorant (guaifenesin 200 mg tablets)
Select Brand Mucus Relief Expectorant (guaifenesin 200 mg)
QC Medifin Expectorant (guaifenesin 200 mg)
Leader Cough Tabs Expectorant (guaifenesin 200 mg)
DECEMBER 2010: MAN UP NOW CAPSULES, A DIETARY SUPPLEMENT FOR SEXUAL ENHANCEMENT RECALLED DUE TO UNDECLARED DRUG INGREDIENT CALLED SULFOAILDENAFIL, A CHEMICAL SIMILAR TO SILDENAFIL (THE ACTIVE INGREDIENT OF VIAGRA). THIS CHEMICAL MAY INTERACT WITH PRESCRIPTION DRUGS SUCH AS NITRATES, INCLUDING NITROGLYCERIN & CAN CAUSE DANGEROUSLY LOW BLOOD PRESSURE.
DECEMBER 2010: ROLAIDS EXTRA STRENGTH SOFTCHEWS, ROLAIDS EXTRA STRENGTH PLUS GAS SOFTCHEWS, ROLAIDS MULTI-SYMPTOM PLUS ANTI-GAS SOFTCHEWS RECALLED DUE TO FOREIGN MATERIALS IN THE PRODUCTS INCLUDING METAL AND WOOD PARTICLES.
DECEMBER 2010: TESSALON (BENZONATATE), MEDICATION FOR RELIEF OF COUGH IN CHILDREN OVER 10 YEARS OLD RECALLED DUE TO ACCIDENTAL INGESTION BY CHILDREN BECAUSE IT LOOKS LIKE CANDY. CHILDREN UNDER 10 CAN RESULT IN DEATH FROM OVERDOSE.
DECEMBER 2010: AVASTIN (BEVACIZUMAB) HAS BEEN RECOMMENDED TO BE REMOVED OUT THE MARKET DUE TO NOT SHOWING SAFE AND EFFECTIVENESS TOWARDS TREATING BREAST CANCER.
DECEMBER 2010: ANZEMET (DOLASNEW CONTRIDICTION ISETRON MESYLATE) RECALLED DUE TO BEING ADDED TO THE PRESCRIBING INFORMATION ADVISING THAT THE INJECTION FORM OF ANZEMET SHOULD NO LONGER BE USED FOR NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY IN PEDIATRIC AND ADULT PATIENTS. NEW DATA DEMONSTRATES THAT ANZEMET INJECTION CAN INCREASE THE RISK OF DEVELOPING TORSADE DE POINTES (AN ABNORMAL HEART RHYTHM), WHICH IN SOME CASES CAN BE FATAL.
DECEMBER 2010: ABBOTT GLUCOSE TEST STRIPES RECALLED DUE TO FALSE LOW BLOOD GLUCOSE RESULTS. THE MARKETED BRAND NAMES ARE PRECISION XCEED PRO, PRECISION XTRA, MEDISENSE OPTIUM, OPTIUM, OPTIUMEZ & RELION ULTIMA. STRIPES EXPOSED TO WARM WEATHER OR PROLONGED STORAGE MAY BE MORE LIKELY TO PROVIDE A FALSE RESULT WHICH WOULD INHIBIT SUFFICIENT ABSORPTION OF THE BLOOD INTO THE TEST STRIP.
DECEMBER 2010: SPECIFIC 19.000 LIPITOR (ATORVASTATIN) 40 MG BOTTLES RECALLED DUE TO AN UNCHARACTERISTIC ODOR. THE ODOR IS CONSISTENT WITH THE PRESENCE OF 2,4,6 TRIBOMOANISOLE (TBA, A CHEMICAL USED FOR A WOOD PRESERVATIVE), FOUND AT A VERY LOW LEVEL DURING INVESTIGATION LEADING TO THE FIRST PRODUCT RECALL.
DECEMBER 2010: DEXAMETHASONE SODIUM PHOSPHATE INJECTION, 4 MG/ML, 30 ML MULTIPLE DOSE VIAL RECALLED DUE TO PATICULATES IN PRODUCT
DECEMBER 2010: SODIUM BICARBONATE INJECTION, USP, 7.5%, 8.4%, 50ML SINGLE DOSE VIALS RECALLED DUE TO PARTICULATES IN SOME VIALS. IF INJECTED WITH THESE SPECIFIC LOTS/VIALS AN ADVERSE EFFECT CAN OCCUR CAUSING DAMAGE TO BLOOD VESSELS IN THE LUNG, LOCALIZED SWELLING, AND GRANULOMA FORMATION.
